Market capitalization | $3.88m |
Enterprise Value | $1.42m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 142.00 |
P/S ratio (TTM) P/S ratio | 388.00 |
P/B ratio (TTM) P/B ratio | 1.03 |
Revenue growth (TTM) Revenue growth | -99.79% |
Revenue (TTM) Revenue | $10.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
2 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.01 0.01 |
100%
100%
|
|
Gross Profit | -1.30 -1.30 |
63%
63%
|
|
EBITDA | -12 -12 |
61%
61%
|
EBIT (Operating Income) EBIT | -14 -14 |
61%
61%
|
Net Profit | -19 -19 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Head office | United States |
CEO | Dale Hogue |
Employees | 1 |
Founded | 2003 |
Website | www.alaunos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.